Full Analysis Set News Today

Topline data were announced from the phase 2/3 HEALEY ALS Platform trial evaluating SLS-005 for amyotrophic lateral sclerosis (ALS).

- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy- Rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assessed by the Myeloproliferati...

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam...

Addition of hemostatic patch complements Ethicon's comprehensive Biosurgery portfolio and ability to address critical unmet needs in controlling bleeding

Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib ...

Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly. See the outlook here.

Cassava Sciences, Inc. announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimers disease dementia. This was an open-label safety study with exploratory... | January 25, 2023

GOTHENBURG, SE / ACCESSWIRE / January 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) a company discovering and developing novel treatments for Parkinson's disease, today announced the top-line results

Ronopterin significantly reduces lactate levels in brain microdialysate from TBI patients reflecting energetic stability and neuroprotection during the early...